Resveratrol 3d structure

GlaxoSmithKline halted its development program of SRT501, a special formulation of resveratrol which is reported to be the active ingredient from red wine, touted as an anti-ageing treatment. GSK obtained the right to develop the compound from Cambridge, Mass.-based Sirtris in 2008 with a $720 million package deal.   

The experimental agent has been studied for several conditions, including Alzheimer’s disease, diabetes, obesity and cancer treatment and prevention.

In May the UK pharma giant said that a clinical trial of the compound  in multiple myeloma patients was halted after kidney damages was found in some patients. The company noted that the particular formulation of Resveratrol ”may only offer minimal efficacy while having a potential to indirectly exacerbate a renal complication common in this patient population, and the company has no further plans to develop SRT501.

The company will continue to develop other SIRT1 activators.  ”We’ve decided to focus our efforts on more selective SIRT1 activator compounds that have no chemical relationship to SRT501 and more favorable drug-like properties,” stated GSK.
 
The follow-on candidate SRT2104 is being studied in a number of  mid-stage clinical trials for  Type 2 diabetes and psoriasis, among other illnesses;  and a third compound, SRT2379, has been put through an early-stage studies recently.
 

Related Articles:

  1. Lilly stops an Alzheimer’s program for disappointing Phase III results
  2. SIRT1, the”Longevity gene” cures Alzheimer’s in mice
  3. Lilly scuttles Phase III diabete program
  4. GSK shows confidence in COPD program, topping up stake in Theravance
  5. Novartis’ COPD program QMF149 delayed